Impact of epidermal fatty acid binding protein on 2D-NMR-assessed atherogenic dyslipidemia and related disorders

Journal of Clinical Lipidology

Volumn 10, Issue 2, 2016, Pages 330-338.e2

  Ibarretxe, Daiana ^a,b   Girona, Josefa ^a,b   Amigó, Núria ^b,c,d   Plana, Núria ^a,b   Ferré, Raimón ^a,b   Guaita, Sandra ^a,b   Mallol, Roger ^b,c,d   Heras, Mercedes ^a,b   Masana, Luis ^a,b  

^a HOSPITAL UNIVERSITARI SANT JOAN DE REUS   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c Biosfer Teslab   (Spain)

^d INSTITUT D INVESTIGACIÓ SANITÀRIA PERE VIRGILI IISPV   (Spain)

Author keywords

Atherogenic dyslipidaemia; Carotid plaque; FABP4; FABP5; hsCRP; Nuclear Magnetic Resonance; Type 2 diabetes

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN A1; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CHOLESTEROL; FATTY ACID BINDING PROTEIN; FATTY ACID BINDING PROTEIN 5; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HIGH SENSITIVITY C REACTIVE PROTEIN; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; FABP4 PROTEIN, HUMAN; FABP5 PROTEIN, HUMAN;

ADULT; AGED; ANAMNESIS; ARTERIAL STIFFNESS; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROGENIC DYSLIPIDEMIA; BODY FAT DISTRIBUTION; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DYSLIPIDEMIA; ECHOGRAPHY; FEMALE; GENETIC VARIATION; GENOTYPE; GLUCOSE METABOLISM; HUMAN; HYPERTENSION; LIPID METABOLISM; LIPOLYSIS; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE; OBESITY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; ATHEROSCLEROSIS; BLOOD; COMPLICATION; GENETICS; METABOLISM; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY;

ADULT; AGED; ATHEROSCLEROSIS; BIOMARKERS; DYSLIPIDEMIAS; FATTY ACID-BINDING PROTEINS; FEMALE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS;

EID: 84955305631     PISSN: 19332874     EISSN: 18764789     Source Type: Journal    
DOI: 10.1016/j.jacl.2015.12.012     Document Type: Article

References (30)

1. J.B. Boord, S. Fazio, and M.F. Linton Cytoplasmic fatty acid-binding proteins: emerging roles in metabolism and atherosclerosis Curr Opin Lipidol 13 2002 141 147
2. M. Furuhashi, S. Ishimura, H. Ota, and T. Miura Lipid chaperones and metabolic inflammation Int J Inflam 2011 2011 642612
3. G. Siegenthaler, R. Hotz, D. Chatellard-Gruaz, L. Didierjean, U. Hellman, and J.H. Saurat Purification and characterization of the human epidermal fatty acid-binding protein: localization during epidermal cell differentiation in vivo and in vitro Biochem J 302 Pt 2 1994 363 371
4. P. Krieg, S. Feil, G. Furstenberger, and G.T. Bowden Tumor-specific overexpression of a novel keratinocyte lipid-binding protein. Identification and characterization of a cloned sequence activated during multistage carcinogenesis in mouse skin J Biol Chem 268 1993 17362 17369
5. L. Makowski, and G.S. Hotamisligil The role of fatty acid binding proteins in metabolic syndrome and atherosclerosis Curr Opin Lipidol 16 2005 543 548
6. M. Furuhashi, and G.S. Hotamisligil Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets Nat Rev Drug Discov 7 2008 489 503
7. A. Xu, Y. Wang, J.Y. Xu, and et al. Adipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome Clin Chem 52 2006 405 413
8. A. Cabre, I. Lazaro, J. Girona, and et al. Plasma fatty acid binding protein 4 is associated with atherogenic dyslipidemia in diabetes J Lipid Res 49 2008 1746 1751
9. A. Cabre, N. Babio, I. Lazaro, and et al. FABP4 predicts atherogenic dyslipidemia development. The PREDIMED study Atherosclerosis 222 2012 229 234
10. A. Cabre, I. Lazaro, J. Girona, and et al. Fatty acid binding protein 4 is increased in metabolic syndrome and with thiazolidinedione treatment in diabetic patients Atherosclerosis 195 2007 e150 e158
11. G.S. Hotamisligil, R.S. Johnson, R.J. Distel, R. Ellis, V.E. Papaioannou, and B.M. Spiegelman Uncoupling of obesity from insulin resistance through a targeted mutation in aP2, the adipocyte fatty acid binding protein Science 274 1996 1377 1379
12. K.T. Uysal, L. Scheja, S.M. Wiesbrock, S. Bonner-Weir, and G.S. Hotamisligil Improved glucose and lipid metabolism in genetically obese mice lacking aP2 Endocrinology 141 2000 3388 3396
13. H. Lan, C.C. Cheng, T.J. Kowalski, and et al. Small-molecule inhibitors of FABP4/5 ameliorate dyslipidemia but not insulin resistance in mice with diet-induced obesity J Lipid Res 52 2011 646 656
14. M. Furuhashi, G. Tuncman, C.Z. Gorgun, and et al. Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2 Nature 447 2007 959 965
15. K. Maeda, K.T. Uysal, L. Makowski, and et al. Role of the fatty acid binding protein mal1 in obesity and insulin resistance Diabetes 52 2003 300 307
16. D.C. Yeung, Y. Wang, A. Xu, and et al. Epidermal fatty-acid-binding protein: a new circulating biomarker associated with cardio-metabolic risk factors and carotid atherosclerosis Eur Heart J 29 2008 2156 2163
17. J. Hong, W. Gu, Y. Zhang, and et al. Different association of circulating levels of adipocyte and epidermal fatty acid-binding proteins with metabolic syndrome and coronary atherosclerosis in Chinese adults Atherosclerosis 217 2011 194 200
18. R. Bagheri, A.N. Qasim, N.N. Mehta, and et al. Relation of plasma fatty acid binding proteins 4 and 5 with the metabolic syndrome, inflammation and coronary calcium in patients with type-2 diabetes mellitus Am J Cardiol 106 2010 1118 1123
19. S. Ishimura, M. Furuhashi, Y. Watanabe, and et al. Circulating levels of fatty acid-binding protein family and metabolic phenotype in the general population PLoS One 8 2013 e81318
20. D.G. Haider, K. Schindler, A. Bohdjalian, and et al. Plasma adipocyte and epidermal fatty acid binding protein is reduced after weight loss in obesity Diabetes Obes Metab 9 2007 761 763
21. D.C. Yeung, A. Xu, A.W. Tso, and et al. Circulating levels of adipocyte and epidermal fatty acid-binding proteins in relation to nephropathy staging and macrovascular complications in type 2 diabetic patients Diabetes Care 32 2009 132 134
22. R. Catala, A. Cabre, S. Hernandez-Flix, and et al. Circulating FABP4 and FABP5 levels are differently linked to OSA severity and treatment Sleep 36 2013 1831 1837
23. L. Bu, L.M. Salto, K.J. De Leon, and M. De Leon Polymorphisms in fatty acid binding protein 5 show association with type 2 diabetes Diabetes Res Clin Pract 92 2011 82 91
24. P.J. Touboul, M.G. Hennerici, S. Meairs, and et al. Mannheim carotid intima-media thickness and plaque consensus (2004-2006-2011). An update on behalf of the advisory board of the 3rd, 4th and 5th watching the risk symposia, at the 13th, 15th and 20th European Stroke Conferences, Mannheim, Germany, 2004, Brussels, Belgium, 2006, and Hamburg, Germany, 2011 Cerebrovasc Dis 34 2012 290 296
25. A. Adji, M.F. O'Rourke, and M. Namasivayam Arterial stiffness, its assessment, prognostic value, and implications for treatment Am J Hypertens 24 2011 5 17
26. I.S. Vlachos, A. Hatziioannou, A. Perelas, and D.N. Perrea Sonographic assessment of regional adiposity AJR Am J Roentgenol 189 2007 1545 1553
27. D.R. Matthews, J.P. Hosker, A.S. Rudenski, B.A. Naylor, D.F. Treacher, and R.C. Turner Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man Diabetologia 28 1985 412 419
28. A.S. Levey, J.P. Bosch, J.B. Lewis, T. Greene, N. Rogers, and D. Roth A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group Ann Intern Med 130 1999 461 470
29. R. Mallol, N. Amigo, M.A. Rodriguez, and et al. Liposcale: a novel advanced lipoprotein test based on 2D diffusion-ordered 1H NMR spectroscopy J Lipid Res 56 2015 737 746
30. P. Oeth, G. del Mistro, G. Marnellos, T. Shi, and D. van den Boom Qualitative and quantitative genotyping using single base primer extension coupled with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MassARRAY) Methods Mol Biol 578 2009 307 343